• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cervical Cancer - Pipeline Review, H2 2012 Product Image

Cervical Cancer - Pipeline Review, H2 2012

  • Published: August 2012
  • 319 pages
  • Global Markets Direct

Cervical Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cervical Cancer - Pipeline Review, H2 2012', provides an overview of the Cervical Cancer therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. 'Cervical Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cervical Cancer.
- A review of the Cervical Cancer products under development by companies and universities/research institutes based on READ MORE >

2
List of Tables 7
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Cervical Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Cervical Cancer 12
Cervical Cancer Therapeutics under Development by Companies 14
Cervical Cancer Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Cervical Cancer Therapeutics – Products under Development by Companies 27
Cervical Cancer Therapeutics – Products under Investigation by Universities/Institutes 30
Companies Involved in Cervical Cancer Therapeutics Development 37
Helix BioPharma Corp. 37
GlaxoSmithKline plc 38
Merck & Co., Inc. 39
YM BioSciences Inc. 40
Amorfix Life Sciences Ltd. 41
MediGene AG 42
Novartis AG 43
Chong Kun Dang Pharmaceutical 44
Taiho Pharmaceutical Co., Ltd. 45
Zeria Pharmaceutical Co Ltd 46
CEL-SCI Corporation 47
Advaxis, Inc. 48
3SBio Inc. 49
Neogenix Oncology Corporation 50
Dendreon Corporation 51
Array BioPharma Inc. 52
Transgene SA 53
LG Life Sciences, Ltd 54
Innocell Corporation 55
Antigen Express, Inc. 56
Nutri Pharma ASA 57
Dafra Pharma International Ltd. 58
ApoImmune, Inc. 59
PDS Biotechnology Corporation 60
Azaya Therapeutics, Inc. 61
ImmunoVaccine Technologies Inc. 62
BT PHARMA 63
PharmaMar, S.A. 64
Genetic Immunity, LLC 65
Advanced Cancer Therapeutics 66
Eurofarma 67
EyeGene, Inc. 68
ISA Pharmaceuticals B.V. 69
Coridon Pty Ltd 70
Cervical Cancer – Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Combination Products 72
Assessment by Route of Administration 73
Assessment by Molecule Type 76
Drug Profiles 79
Cisplatin + Radiation Therapyy - Drug Profile 79
PDS0101 - Drug Profile 80
ATI-1123 - Drug Profile 81
Multikine - Drug Profile 83
CA-9 - Drug Profile 85
Interferon Alpha-2b - Drug Profile 86
SSS08 Vaccine - Drug Profile 87
ASLAN001 - Drug Profile 88
ADXS-HPV - Drug Profile 90
ApoVax104-HPV - Drug Profile 92
ProCervix - Drug Profile 93
Z-100 - Drug Profile 94
V503 - Drug Profile 95
Zalypsis - Drug Profile 96
Paclitaxel + Cisplatin - Drug Profile 97
Sorafenib + Cisplatin + Radiation Therapy - Drug Profile 99
Vinorelbine + Paclitaxel + Radiation Therapy - Drug Profile 100
AZD2171 + Temsirolimus - Drug Profile 102
Avastin + Radiation Therapy - Drug Profile 103
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 104
Cisplatin - Drug Profile 106
Fluorouracil + Doxorubicin - Drug Profile 107
Isotretinoin + Interferon Alpha 2a - Drug Profile 108
Cisplatin + Navelbine - Drug Profile 109
Cisplatin - Drug Profile 111
Cisplatin + Amifostine - Drug Profile 114
Tirapazamine + Cisplatin + Radiation Therapy - Drug Profile 116
Gemcitabine + Cisplatin - Drug Profile 118
SU11248 - Drug Profile 120
Gemcitabine + Cisplatin - Drug Profile 121
CCI-779 - Drug Profile 123
BMS-247550 - Drug Profile 124
Cetuximab + Cisplatin - Drug Profile 126
Eflornithine - Drug Profile 127
Paclitaxel + Carboplatin - Drug Profile 128
Hycamtin - Drug Profile 130
Docetaxel - Drug Profile 132
pNGVL4a-Sig/E7(Detox)/HSP70 DNA Vaccine - Drug Profile 133
HPV Vaccine - Drug Profile 134
Bevacizumab - Drug Profile 135
Etoposide - Drug Profile 137
Tirapazamine + Cisplatin - Drug Profile 138
Carboplatin + Paclitaxel - Drug Profile 139
Multimeric-L2 Protein Vaccine - Drug Profile 141
Tykerb + Votrient - Drug Profile 142
Cisplatin + Alimta - Drug Profile 144
Topotecan + Cisplatin + Radiation Therapy - Drug Profile 145
Phyxol + Cisplatin - Drug Profile 147
S-1 + Cisplatin - Drug Profile 148
Epoetin alfa + Cisplatin + Brachytherapy + Radiation therapy - Drug Profile 150
Gardasil - Drug Profile 151
BMS582664 - Drug Profile 152
Topotecan + Paclitaxel - Drug Profile 153
Bevacizumab + Paclitaxel + Topotecan - Drug Profile 154
Topotecan + Cisplatin - Drug Profile 155
Bevacizumab + Cisplatin + Paclitaxel - Drug Profile 157
Nelfinavir + Cisplatin - Drug Profile 159
Cisplatin - Drug Profile 161
5-Fluorouracil + Interferon-a + Doxorubicin + Hyperthermia - Drug Profile 163
Carboplatin + Cisplatin + Paclitaxel - Drug Profile 164
Topotecan + Cisplatin + Bevacizumab - Drug Profile 166
Cisplatin + Radiation Therapy - Drug Profile 167
Cisplatin + Gemcitabine + Radiation Therapy - Drug Profile 169
Paclitaxel + Cisplatin - Drug Profile 170
Immuncell-LC - Drug Profile 171
Paclitaxel + Topotecan - Drug Profile 173
Cisplatin + Radiation Therapy - Drug Profile 174
Carboplatin + Paclitaxel + Cediranib - Drug Profile 175
Paclitaxel + Topotecan - Drug Profile 176
HLA-A-0201 Restricted Specific Epitope Peptides - Drug Profile 177
HLA-A-2402 Restricted Specific Epitope Peptide - Drug Profile 178
Irinotecan + Nedaplatin - Drug Profile 179
Panitumumab + Cisplatin + Radiation Therapy - Drug Profile 180
Cisplatin + Radiation Therapy - Drug Profile 181
CDDP + Paclitaxel - Drug Profile 182
Taxol - Drug Profile 183
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 186
Gendicine + Radiation Therapy - Drug Profile 187
Velcade + Radiation Therapy - Drug Profile 188
Topotecan + Cisplatin - Drug Profile 189
TG4001 - Drug Profile 190
Docetaxel + Carboplatin - Drug Profile 191
Paclitaxel + Cisplatin - Drug Profile 192
Hycamtin + Platinol - Drug Profile 194
Cetuximab + Cisplatin + Radiotherapy - Drug Profile 195
Cetuximab + Cisplatin + Radiotherapy - Drug Profile 196
Triapine + Cisplatin + Radiation Therapy - Drug Profile 197
Docetaxel + Tariquidar - Drug Profile 199
Cyclophosphamide - Drug Profile 200
Bevacizumab + Cisplatin - Drug Profile 201
Sorafenib + Cisplatin + radiation theraphy - Drug Profile 203
Topotecan + Carboplatin - Drug Profile 204
Pegylated Liposomal Doxorubicin Hydrochloride + Carboplatin - Drug Profile 205
Imiquimod - Drug Profile 206
Cisplatin + Radiation Therapy + Hyperthermia Therapy - Drug Profile 207
Cisplatin - Drug Profile 208
Platinex + Radiation Therapy - Drug Profile 210
Fluorouracil + Radiation Therapy - Drug Profile 211
SGN-00101 Vaccine - Drug Profile 212
Topotecan - Drug Profile 213
RAD001 + Cisplatin - Drug Profile 215
Alimta - Drug Profile 217
Cisplatin + Gemcitabine - Drug Profile 218
Bleomycin + Mitomycin C + Cisplatin - Drug Profile 219
Carboplatin - Drug Profile 220
Carboplatin + Paclitaxel + Cediranib Maleate - Drug Profile 221
Cisplatin + Radiation Therapy - Drug Profile 223
Paclitaxel + Cispaltin + Radiotherapy - Drug Profile 224
Mapatumumab + Cisplatin + Radiotherapy - Drug Profile 226
Uracil-Tegafur + Radiation Therapy - Drug Profile 227
Artesunate - Drug Profile 228
Cisplatin + Radiation Therapy - Drug Profile 229
Topotecan + Cisplatin + Radiation Therapy - Drug Profile 230
Autologous Immune Cell Therapy + Radiation Therapy - Drug Profile 232
HPV Vaccine - Drug Profile 234
Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 235
HupaDerm Vaccine - Drug Profile 237
Paclitaxel + Cisplatin - Drug Profile 238
CIGB 228 - Drug Profile 239
CIGB-300 - Drug Profile 240
Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile 241
Cisplatin + Radiation Therapy - Drug Profile 243
HPV Vaccine - Drug Profile 244
Cisplatin + Vinorelbine + Nimotuzumab - Drug Profile 245
TS-1 - Drug Profile 246
Nimotuzumab + Cisplatin - Drug Profile 247
RBT-201 - Drug Profile 249
Paclitaxel + Nedaplatin - Drug Profile 250
Squamous Antibodies - Drug Profile 251
Cidofovir - Drug Profile 252
Ifosfamide + Paclitaxel + Carboplatin - Drug Profile 253
AEH10p - Drug Profile 254
Paclitaxel + Cisplatin + ABT-888 - Drug Profile 255
Adeno-Associated Virus-Like Particles - Drug Profile 257
ISA-HPV-SLP - Drug Profile 259
Cervlysin - Drug Profile 260
ONS-1035 - Drug Profile 261
Docetaxel + Carboplatin - Drug Profile 263
EG-HPV - Drug Profile 265
Human Papillomavirus Vaccine - Drug Profile 266
Paclitaxel + Carboplatin + Cisplatin - Drug Profile 267
CKD-12201 - Drug Profile 269
Anti-Fas - Drug Profile 270
Cervical Cancer Therapeutics – Drug Profile Updates 271
Cervical Cancer Therapeutics – Discontinued Products 288
Cervical Cancer Therapeutics - Dormant Products 290
Cervical Cancer – Product Development Milestones 301
Featured News & Press Releases 301
Appendix 308
Methodology 308
Coverage 308
Secondary Research 308
Primary Research 308
Expert Panel Validation 308
Contact Us 309
Disclaimer 309

List of Tables
Number of Products Under Development for Cervical Cancer, H2 2012 22
Products under Development for Cervical Cancer – Comparative Analysis, H2 2012 23
Number of Products under Development by Companies, H2 2012 25
Number of Products under Development by Companies, H2 2012 (Contd..1) 26
Number of Products under Development by Companies, H2 2012 (Contd..2) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 32
Comparative Analysis by Late Stage Development, H2 2012 33
Comparative Analysis by Mid Clinical Stage Development, H2 2012 34
Comparative Analysis by Early Clinical Stage Development, H2 2012 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 36
Products under Development by Companies, H2 2012 37
Products under Development by Companies, H2 2012 (Contd..1) 38
Products under Development by Companies, H2 2012 (Contd..2) 39
Products under Investigation by Universities/Institutes, H2 2012 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 46
Helix BioPharma Corp., H2 2012 47
GlaxoSmithKline plc, H2 2012 48
Merck & Co., Inc., H2 2012 49
YM BioSciences Inc., H2 2012 50
Amorfix Life Sciences Ltd., H2 2012 51
MediGene AG, H2 2012 52
Novartis AG, H2 2012 53
Chong Kun Dang Pharmaceutical, H2 2012 54
Taiho Pharmaceutical Co., Ltd., H2 2012 55
Zeria Pharmaceutical Co Ltd, H2 2012 56
CEL-SCI Corporation, H2 2012 57
Advaxis, Inc., H2 2012 58
3SBio Inc., H2 2012 59
Neogenix Oncology Corporation, H2 2012 60
Dendreon Corporation, H2 2012 61
Array BioPharma Inc., H2 2012 62
Transgene SA, H2 2012 63
LG Life Sciences, Ltd, H2 2012 64
Innocell Corporation, H2 2012 65
Antigen Express, Inc., H2 2012 66
Nutri Pharma ASA, H2 2012 67
Dafra Pharma International Ltd., H2 2012 68
ApoImmune, Inc., H2 2012 69
PDS Biotechnology Corporation, H2 2012 70
Azaya Therapeutics, Inc., H2 2012 71
ImmunoVaccine Technologies Inc., H2 2012 72
BT PHARMA, H2 2012 73
PharmaMar, S.A., H2 2012 74
Genetic Immunity, LLC, H2 2012 75
Advanced Cancer Therapeutics, H2 2012 76
Eurofarma, H2 2012 77
EyeGene, Inc., H2 2012 78
ISA Pharmaceuticals B.V., H2 2012 79
Coridon Pty Ltd, H2 2012 80
Assessment by Monotherapy Products, H2 2012 81
Assessment by Combination Products, H2 2012 82
Assessment by Stage and Route of Administration, H2 2012 85
Assessment by Stage and Molecule Type, H2 2012 88
Cervical Cancer Therapeutics – Drug Profile Updates 281
Cervical Cancer Therapeutics – Discontinued Products 298
Cervical Cancer Therapeutics – Discontinued Products (Contd..1) 299
Cervical Cancer Therapeutics – Dormant Products 300
Cervical Cancer Therapeutics – Dormant Products (Contd..1) 301
Cervical Cancer Therapeutics – Dormant Products (Contd..2) 302
Cervical Cancer Therapeutics – Dormant Products (Contd..3) 303
Cervical Cancer Therapeutics – Dormant Products (Contd..4) 304
Cervical Cancer Therapeutics – Dormant Products (Contd..5) 305
Cervical Cancer Therapeutics – Dormant Products (Contd..6) 306
Cervical Cancer Therapeutics – Dormant Products (Contd..7) 307
Cervical Cancer Therapeutics – Dormant Products (Contd..8) 308
Cervical Cancer Therapeutics – Dormant Products (Contd..9) 309
Cervical Cancer Therapeutics – Dormant Products (Contd..10) 310

List of Figures
Number of Products under Development for Cervical Cancer, H2 2012 22
Products under Development for Cervical Cancer – Comparative Analysis, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 28
Late Stage Products, H2 2012 33
Mid Clinical Stage Products, H2 2012 34
Early Clinical Stage Products, H2 2012 35
Discovery and Pre-Clinical Stage Products, H2 2012 36
Assessment by Monotherapy Products, H2 2012 81
Assessment by Combination Products, H2 2012 82
Assessment by Route of Administration, H2 2012 83
Assessment by Stage and Route of Administration, H2 2012 84
Assessment by Molecule Type, H2 2012 86
Assessment by Stage and Molecule Type, H2 2012 87

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos